PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
暂无分享,去创建一个
P. Tassone | P. Tagliaferri | A. Giordano | L. Mutti | L. Pirtoli | C. Botta | P. Correale | C. Gandolfo | M. G. Cusi | V. Nardone | B. Oliva | D. Azzarello | R. Giannicola | A. Falzea | Mojtaba Shekarkar Azgomi | R. Saladino | N. D. Calandruccio | M. Monoriti | Giovanna Bianco | Antonella Fameli | C. Romeo | M. Cusi | Marika Monoriti
[1] Qian Zhang,et al. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis , 2021, Cancer Chemotherapy and Pharmacology.
[2] P. Tassone,et al. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis , 2021, Life.
[3] H. Goldschmidt,et al. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology , 2021, Blood advances.
[4] Elisa Catafal-Tardos,et al. Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells , 2021, Cancers.
[5] S. Zappavigna,et al. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade , 2021, Frontiers in Oncology.
[6] W. Jiao,et al. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress , 2020, Frontiers in Pharmacology.
[7] P. Tassone,et al. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis , 2020, Cells.
[8] P. Tassone,et al. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade , 2020, Journal for immunotherapy of cancer.
[9] A. Dietz,et al. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. , 2020, Thyroid : official journal of the American Thyroid Association.
[10] P. Tagliaferri,et al. Could PD-1/PDL1 immune checkpoints be linked to HLA signature? , 2019, Immunotherapy.
[11] B. Duysinx,et al. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels , 2019, Acta oncologica.
[12] P. Tassone,et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. , 2019, Molecular and clinical oncology.
[13] G. Eapen,et al. Lung Cancer. , 2019, The Medical clinics of North America.
[14] L. Xia,et al. PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions , 2019, The oncologist.
[15] M. Najafi,et al. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.
[16] Yoon Dae Han,et al. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. , 2018, Cancer research.
[17] C. Klein,et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.
[18] Ahmet Zehir,et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[20] C. Rudin,et al. Atezolizumab for the treatment of non-small cell lung cancer , 2017, Expert review of clinical pharmacology.
[21] I. Preeshagul,et al. New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab , 2017, Lung Cancer.
[22] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[23] Ignacio I Wistuba,et al. Lung Cancer Biomarkers. , 2017, Hematology/oncology clinics of North America.
[24] P. Tassone,et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients , 2016, Cell Death Discovery.
[25] P. Tassone,et al. The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response , 2016, Cell Death and Disease.
[26] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[27] P. Tassone,et al. Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients: The GOLFIG-2 Multicentric Open-label Randomized Phase III Trial , 2014, Journal of immunotherapy.
[28] A. Rossi,et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients , 2013, Cancer biology & therapy.
[29] A. Fioravanti,et al. Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen , 2012, Journal of chemotherapy.
[30] P. Tassone,et al. Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) , 2008, Clinical Cancer Research.
[31] C. Miracco,et al. Occurrence of Autoimmunity in a Long-Term Survivor with Metastatic Colon Carcinoma Treated with a New Chemo-Immunotherapy Regimen , 2008, Journal of chemotherapy.
[32] Stuart Moss,et al. Current Status and Future Directions , 2013 .
[33] Robert C. Wolpert,et al. A Review of the , 1985 .